AZN.UK

11,254

-1.07%↓

GSK

1,474.5

+0.14%↑

HLN.UK

340.6

-0.58%↓

STJ

1,259.5

+0.96%↑

HIK

1,630

+0.62%↑

AZN.UK

11,254

-1.07%↓

GSK

1,474.5

+0.14%↑

HLN.UK

340.6

-0.58%↓

STJ

1,259.5

+0.96%↑

HIK

1,630

+0.62%↑

AZN.UK

11,254

-1.07%↓

GSK

1,474.5

+0.14%↑

HLN.UK

340.6

-0.58%↓

STJ

1,259.5

+0.96%↑

HIK

1,630

+0.62%↑

AZN.UK

11,254

-1.07%↓

GSK

1,474.5

+0.14%↑

HLN.UK

340.6

-0.58%↓

STJ

1,259.5

+0.96%↑

HIK

1,630

+0.62%↑

AZN.UK

11,254

-1.07%↓

GSK

1,474.5

+0.14%↑

HLN.UK

340.6

-0.58%↓

STJ

1,259.5

+0.96%↑

HIK

1,630

+0.62%↑

Search

Oxford Biomedica PLC

Atvērts

576 -1.87

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

565

Max

593

Galvenie mērījumi

By Trading Economics

Ienākumi

-11M

Pārdošana

78M

EPS

-0.11

Peļņas marža

-13.726

Darbinieki

850

EBITDA

5M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+6.6% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 23. sept.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

740M

Iepriekšējā atvēršanas cena

577.87

Iepriekšējā slēgšanas cena

576

Oxford Biomedica PLC Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 17. sept. 23:01 UTC

Iegādes, apvienošanās, pārņemšana

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

2025. g. 17. sept. 22:48 UTC

Iegādes, apvienošanās, pārņemšana

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

2025. g. 17. sept. 21:59 UTC

Peļņas

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

2025. g. 17. sept. 23:44 UTC

Tirgus saruna

Nikkei May Rise as Yen Weakens -- Market Talk

2025. g. 17. sept. 23:39 UTC

Tirgus saruna

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

2025. g. 17. sept. 22:20 UTC

Iegādes, apvienošanās, pārņemšana

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

2025. g. 17. sept. 22:20 UTC

Iegādes, apvienošanās, pārņemšana

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

2025. g. 17. sept. 22:20 UTC

Iegādes, apvienošanās, pārņemšana

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

2025. g. 17. sept. 22:19 UTC

Iegādes, apvienošanās, pārņemšana

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

2025. g. 17. sept. 22:18 UTC

Iegādes, apvienošanās, pārņemšana

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

2025. g. 17. sept. 21:00 UTC

Peļņas

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

2025. g. 17. sept. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 17. sept. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 17. sept. 19:59 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 17. sept. 19:59 UTC

Tirgus saruna

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

2025. g. 17. sept. 19:07 UTC

Tirgus saruna

Oil Futures Snap Three-Session Winning Streak -- Market Talk

2025. g. 17. sept. 18:43 UTC

Tirgus saruna

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

2025. g. 17. sept. 18:38 UTC

Tirgus saruna

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

2025. g. 17. sept. 18:20 UTC

Tirgus saruna

Gold Dips After Quarter-Point Rate Cut -- Market Talk

2025. g. 17. sept. 18:18 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 17. sept. 18:18 UTC

Tirgus saruna

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

2025. g. 17. sept. 18:14 UTC

Tirgus saruna

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

2025. g. 17. sept. 17:59 UTC

Tirgus saruna

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

2025. g. 17. sept. 17:15 UTC

Iegādes, apvienošanās, pārņemšana

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

2025. g. 17. sept. 17:06 UTC

Iegādes, apvienošanās, pārņemšana

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

2025. g. 17. sept. 16:51 UTC

Peļņas

Correct: Exor 1H Net Loss -EUR624M

2025. g. 17. sept. 16:34 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 17. sept. 16:34 UTC

Tirgus saruna

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

2025. g. 17. sept. 16:25 UTC

Peļņas

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

2025. g. 17. sept. 16:23 UTC

Peļņas

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Salīdzinājums

Cenas izmaiņa

Oxford Biomedica PLC Prognoze

Cenas mērķis

By TipRanks

6.6% augšup

Prognoze 12 mēnešiem

Vidējais 617.207 GBX  6.6%

Augstākais 930 GBX

Zemākais 400 GBX

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Oxford Biomedica PLC — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

4 ratings

3

Pirkt

1

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Oxford Biomedica PLC

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.
help-icon Live chat